1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids

Collaboration Is Latest Focused On Next-Generation Gene Therapies

 
• By Alaric DeArment

Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.

Scientific vector illustration genetic engineering and gene manipulation concept. DNA helix, DNA strand, molecule or atom, neurons. Abstract structure for Science or medical background.
Biogen and Capsigen ink a $1.3bn deal for improved AAV capsids • Source: Shutterstock

A $1.3bn deal between Biogen, Inc. and Capsigen Inc. points to how a growing number of large biopharma companies are turning to small firms focused on developing novel capsid technology to aid their gene therapy development efforts. Along with that, there is growing interest in adeno-associated viral (AAV) vector-based gene therapies more specifically tailored to diseases than the ones currently on the market, and the firms’ ability to net potentially billion-dollar-plus deals shows there is room for better capsids.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 
• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 
• By Alaric DeArment

Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.

More from Advanced Therapies

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 
• By Alaric DeArment

Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.

Atsena To Advance XLRS Gene Therapy With Latest Funding Round

 
• By Alaric DeArment

The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.